As of the new year 2025, 225 million men will suffer from erectile dysfunction (ED) with disastrous consequences for their personal and family lives. For nearly 50 years, Dr.Ronald Virag, a cardiovascular surgeon, joined in 1984 by Dr.Helene Sussman, a chemical engineer and then vascular doctor, has dedicated his scientific life to finding the best solutions to overcome ED. Together, they founded CETI®, the Center for Exploration and Treatment of Impotence, which has successfully treated over 25,000 men and/or couples. At the same time, their discoveries have transformed the diagnosis and treatment of ED: intracavernous injections in 1982, vascular explorations of erection, vascular surgical treatments, and the global concept of ED diagnosis and treatment.
Today, they aim to spread this knowledge and make their diagnostic and treatment methods accessible to everyone, while equipping themselves with the means to continually advance their concept.
To achieve this, they are launching two entities:
• CETI Development Ltd. – responsible for developing CETI® centers worldwide, based on the model of the “Paris Pilot Center,” with its diagnostic and therapeutic methods, including the provision of CERITINE® and EllioVir®.
• CETI IT Ltd. – responsible for developing IT logistical support for ED diagnosis and treatments through a platform that integrates all collected data while continuing clinical research authorized by the exploitation of the collected data.
NOTES
CERITINE®
Discovered and published as early as 1982 (R. Virag – Lancet), the erectile effects of medications injected into the penis remain today the most effective medical treatment for ED. The patient discreetly injects themselves before sexual activity after easy training with a specialist. CERITINE®, an internationally patented formulation (SOLO envelope notarized), tested and improved over nearly forty years of practice, has arrived at the most effective and safest formula today.
The main advantages of the self-injection concept are:
• Local action only (no side effects on the body)
• Supra-physiological reactions: duration independent of ejaculation, elimination of the frequent and devastating fear of sexual failure
• Autonomy in managing the treatment once the patient has mastered the technique
• Reversibility of the erection by the patient using a specific antidote, etilefrine (in the rare case of prolonged erection)
• The potential competitor, alprostadil marketed under the name Edex (CSP) or Caverject (Pfizer), is significantly less effective, often painful (for 30% of users), and lacks the extended erection management system. Other products on the market, such as Androskat® or Invicorp®, are less effective. As for Trimix-labeled mixtures, they are merely a simplification of CERITINE®.